Company Profile
Liquidia Corporation Stock Price, News & Analysis
- Ticker:
- LQDA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
89.42 USD (+0.34%)
Close
Last updated: August 6, 2026
4.9B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, LQDA closed up 0.34% at $89.42. No new same-company headline was identified in the current news window.
Company overview
Pulmonary Hypertension Company
Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve the delivery of established medicines.
YUTREPIA
YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
PRINT Technology
The company's PRINT manufacturing platform produces particles with controlled size, shape and composition. Liquidia uses this capability to create inhaled formulations intended to simplify administration and support dose flexibility.
Future catalysts
Liquidia’s catalysts are still centered on YUTREPIA launch execution and any additional regulatory or commercial step around inhaled treprostinil. The market will care about whether the company can keep converting approval into durable adoption in pulmonary hypertension.
Recent news
- 01
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
Source: Liquidia Corporation
- 02
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
Source: Liquidia Corporation
- 03
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
Source: Liquidia Corporation
- 04
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Source: Liquidia Corporation
- 05
Liquidia Corporation Reports First Quarter 2026 Financial Results
Source: Liquidia Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Liquidia Corporation (LQDA)?
Liquidia Corporation (LQDA) most recently closed at 89.42 USD, a +0.34% move versus the previous session.
What is the market cap of Liquidia Corporation (LQDA)?
Liquidia Corporation currently has a market capitalization of 4.9B USD on BioPharmSignal.
What does Liquidia Corporation do?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve the delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United...
On which exchange is LQDA stock listed?
Liquidia Corporation (LQDA) is associated with NASDAQ, United States, Biopharma.
What is Pulmonary?
The market will care about whether the company can keep converting approval into durable adoption in pulmonary hypertension.
Which conditions is Liquidia Corporation targeting with Pulmonary?
The market will care about whether the company can keep converting approval into durable adoption in pulmonary hypertension.
How does Liquidia Corporation describe recent progress with Pulmonary?
The market will care about whether the company can keep converting approval into durable adoption in pulmonary hypertension.
What is Hypertension?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension.